Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
The NCCN published its first guidelines for pediatric bone sarcoma, centering on Ewing sarcoma and other undifferentiated round cell sarcomas in youth for pediatric patients.